ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Acquired by Swiss National Bank

Swiss National Bank increased its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 212,104 shares of the biopharmaceutical company’s stock after purchasing an additional 2,900 shares during the period. Swiss National Bank’s holdings in ACADIA Pharmaceuticals were worth $3,892,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in ACADIA Pharmaceuticals in the 4th quarter worth about $47,000. Quest Partners LLC boosted its position in shares of ACADIA Pharmaceuticals by 42.3% in the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 1,047 shares during the last quarter. KBC Group NV grew its holdings in ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 2,044 shares during the period. PDT Partners LLC acquired a new position in ACADIA Pharmaceuticals during the third quarter worth approximately $203,000. Finally, Personal CFO Solutions LLC purchased a new position in ACADIA Pharmaceuticals during the fourth quarter worth approximately $224,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Price Performance

NASDAQ:ACAD opened at $17.11 on Wednesday. The firm has a 50-day moving average of $18.36 and a two-hundred day moving average of $17.02. The stock has a market cap of $2.85 billion, a P/E ratio of 21.94 and a beta of 0.43. ACADIA Pharmaceuticals Inc. has a 1-year low of $14.15 and a 1-year high of $20.68.

Analysts Set New Price Targets

Several analysts have recently issued reports on ACAD shares. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They set a “hold” rating and a $22.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Guggenheim lowered ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.93.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the sale, the director now owns 17,595 shares in the company, valued at approximately $320,756.85. This represents a 21.85 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 6,167 shares of company stock valued at $114,583 in the last three months. Corporate insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.